Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Less than 18 months after Beam Therapeutics launched with its first round of private funding, the gene-editing start-up has filed paperwork for a $100 million initial public offering on Nasdaq. Beam is developing therapies derived from the CRISPR base editors invented in David Liu’s lab at the Broad Institute of MIT & Harvard. Liu’s editors, published in 2016, can change a single nucleotide of DNA into another nucleotide. Beam is working on 12 drug programs, with an initial focus on blood, liver, and eye diseases, as well as CAR T-cell therapies.
This article has been sent to the following recipient: